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Abstract
Background: The ventricular system plays a vital role in blood-cerebrospinal fluid (CSF) exchange and interstitial
fluid-CSF drainage pathways. CSF is formed in the specialized secretory tissue called the choroid plexus, which
consists of epithelial cells, fenestrated capillaries and the highly vascularized stroma. Very little is currently known
about the role played by the ventricles and the choroid plexus tissue in aging and Alzheimer’s disease (AD).
Methods: In this study, we used our state-of-the-art proteomic platform, a liquid chromatography/mass
spectrometry (LC-MS/MS) approach coupled with Tandem Mass Tag isobaric labeling to conduct a detailed
unbiased proteomic analyses of autopsied tissue isolated from the walls of the inferior horn of the lateral ventricles
in AD (77.2 ± 0.6 yrs), age-matched controls (77.0 ± 0.5 yrs), and nonagenarian cases (93.2 ± 1.1 yrs).
Results: Ingenuity pathway analyses identified phagosome maturation, impaired tight-junction signaling, and
glucose/mannose metabolism as top significantly regulated pathways in controls vs nonagenarians. In matched-
control vs AD cases we identified alterations in mitochondrial bioenergetics, oxidative stress, remodeling of
epithelia adherens junction, macrophage recruitment and phagocytosis, and cytoskeletal dynamics. Nonagenarian
vs AD cases demonstrated augmentation of oxidative stress, changes in gluconeogenesis-glycolysis pathways, and
cellular effects of choroidal smooth muscle cell vasodilation. Amyloid plaque score uniquely correlated with
remodeling of epithelial adherens junctions, Fc γ-receptor mediated phagocytosis, and alterations in RhoA signaling.
Braak staging was uniquely correlated with altered iron homeostasis, superoxide radical degradation and
phagosome maturation.
Conclusions: These changes provide novel insights to explain the compromise to the physiological properties and
function of the ventricles/choroid plexus system in nonagenarian aging and AD pathogenesis. The pathways
identified could provide new targets for therapeutic strategies to mitigate the divergent path towards AD.
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Background
The interstitial fluid (ISF) of the brain tissue and the
cerebrospinal fluid (CSF) bathing the CNS are essential
for providing a stable homeostatic and metabolic brain
environment for neuronal function [1, 2]. They are also
integral to maintaining adequate clearance of neuronal
and glia waste products from the brain as a result of
their ongoing metabolic activities. In late-onset Alzhei-
mer’s disease (AD), it is becoming increasingly evident
that inefficient brain clearance mechanisms may be the
main driver for the accumulation of toxic proteinaceous
aggregates [3–5]. For example, in pathological ageing
potentially pathogenic Tau aggregates have been ob-
served in and along the fluids of the brain, in periarter-
ial/perivascular space, subependymal cells lining the
walls of the ventricles, and subpial glial cells that form
the glial limitans lining the brain parenchyma [6–14].
Cerebral amyloid angiopathy is also preferentially local-
ized around leptomeningeal arteries between the pia and
arachnoid compartments of the brain [11]. Thus, indi-
cating that there may be abnormalities in the movement
and clearance of solutes in brain fluids around these
ventricular sites, and other CSF compartments that
could contribute to tau/amyloid pathologies.
CSF is critical for brain clearance, it is produced from
arterial blood by the choroid plexus located in the lateral
and fourth ventricles, which consists of tufts of capillar-
ies with an inner layer of fenestrated endothelial cells, an
underlying thin layer of highly vascularized stroma, and
an epithelial covering or lining of specialized apical
ependymal cells with bulbous microvilli [1, 15]. CSF
formation involves an active secretion process by these
modified ependymal cells that forms the epithelial lining
surrounding the plexus, involving pumps, co-
transporters, antiporters, ion channels and aquaporins
[1, 15]. The ventricular system has a variety of roles in
brain physiology, but very little is currently known about
the role(s) they play in ageing and AD pathogenesis, and
how this may influence tau and amyloid proteinopathies.
Waste products (e.g. proteins) produced by neurons
and glia can pass from the brain parenchyma by ISF
convective bulk flow, moving through the ependymal
ventricular lining and the glial limitans, to mix into the
CSF for clearance into the venous circulation and
lymphatic vessels around the cranial and spinal canal
[1]. In the young adult CNS there is a volume of 160mls
of CSF, and constant replenishment of this volume (4
times a day) is critical for the maintenance of extracellu-
lar fluid homeostasis [16]. This is accomplished by the
modified choroidal ependymal cells which produces CSF
at a rate of 0.3–0.6 ml per minute or 500–600 ml per
day [16]. Balance of CSF formation and reabsorption is
essential to the maintenance of CSF pressure, which has
to be slightly greater than venous pressure in the dural
sinuses to enable CSF absorption through arachnoid
granulations/ villi (i.e. valve like structures) within the
walls of the venous sinuses [16]. The epithelial lining of
the ventricles also aids in the circulation of CSF through
pulsations mediated by the motion of their specialized
ciliated ependymal cells and the arterial hemodynamics
in the plexus [2]. A tightly sealed barrier between the
CSF and the blood, termed the blood-CSF barrier
(BCSFB), is also formed by the tight junctions of these
specialized choroid plexus ependymal cells which serves
to inhibit paracellular diffusion of water-soluble mole-
cules into the CSF. The BCSFB also serves as another
site of waste clearance from the CSF into the blood.
Ependymal cells forming the epithelial lining of the ven-
tricles and their neighboring cells also have a prominent
role as a secretory engine, producing growth factors and
transporting hormones for neuroendocrine signaling
[17]. They continuously regulate the chemical exchange
between the CSF and the brain tissue, and the ionic en-
vironment (e.g. Ka+, Ca2+, HCO3-) of the brain fluids
[1]. They are also one of the main sites for immune cell
recruitment into the brain, and are involved in continu-
ally surveying the immunological status of the CSF [17].
In advanced ageing and/or AD cases, reports of alter-
ations in BCSFB integrity and transporters accompanied
by deficiencies in CSF production, enlargement of ven-
tricular volume, increase in arachnoid villi resistance,
and a reduction in the rate of lymphatic absorption have
been documented [18–23]. If persistent, such alterations
can have deleterious effects on brain physiology, leading
to impaired efflux clearance of CSF waste products and
influx of water soluble molecules directly into the brain,
abnormalities in CSF production and circulation, irregu-
lar CSF pressure, edema formation, and altered recruit-
ment of inflammatory cells into the CNS amongst a host
of other outcomes. It remains unknown what chronic
sequelae of events are responsible for driving the afore-
mentioned age-related pathological changes observed in
advanced ageing and AD.
Given the essential role of ependymal/epithelial cells,
along with other neighboring cell types that forms the
lining of the walls of the ventricles, in CSF fluid bio-
functions, neuroendocrine function and immune cell re-
cruitment, in this study we propose to explore the role
that molecular abnormalities in this brain region may
play in AD pathogenesis. Our hypothesis posits that the
molecular integrity in the walls of brain ventricles of AD
patients is significantly worse than controls and unde-
mented cases, and this may contribute to the molecular
consequences of AD pathogenesis (primarily tauopathy
and amyloidopathy).
To address this, we will use our state-of-the-art
unbiased proteomic platform, a liquid chromatography/
mass spectrometry (LC-MS) approach coupled with
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Tandem Mass Tag isobaric labeling to conduct a de-
tailed characterization and assessment of molecular
changes in protein expression levels, and identify mo-
lecular pathways and biofunctions significantly altered in
autopsied tissue isolated from the walls of the inferior
horn of the lateral ventricles in AD (77.2 ± 0.6 yrs), age-
matched controls (77.0 ± 0.5 yrs), and nonagenarian
cases (93.2 ± 1.1 yrs). Unbiased proteomic analysis is a
powerful tool which can provide a very expansive inter-
rogation of the molecular response to diseases in a range
of biomaterials. In this study we detail the unique prote-
omic profiles in isolated tissue from the superior part of
the walls of the inferior horn of the lateral ventricles of
AD and age-matched controls and nonagenarian
patients with cognitive resilience.
Methods
Brain tissue
Human brain tissue samples from the superior part of
the walls of the inferior horn of the lateral ventricles
were obtained from the NIH NeuroBioBank at the Ican
School of Medicine at Mount Sinai (New York, NY) in
accordance with the institutional bioethics guidelines.
All donors and their families gave written informed con-
sent for autopsy and use of brain tissue for research pur-
poses. As samples were obtained from deceased, de-
identified, consenting individuals, no further ethical ap-
proval was required. On average, the autopsies were per-
formed within 6–10 h after death. An overview of the
demographics, clinical information and post-mortem
variables of all brain donors used in this study is sum-
marized in Table 1A-B. Neuropathological diagnosis of
AD was determined using the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) diagnostic
criteria [24] as well as the consensus recommendation
for postmortem diagnosis of AD by the National Insti-
tute for Aging/Reagan Institute Working Group [25].
Neurofibrillary Tangle (NFT) distribution using the
Braak staging method [26].
Protein extraction
Frozen brain tissue blocks from the walls of the ventri-
cles were homogenized in a 2.5fold weight per volume
of LC/MS grade chilled water. 50 u l of homogenized
tissue were added to a 50 u l aqueous buffer solution
consisting of 2X PBS, 2X NaCl and cocktail of protein-
ase inhibitor. These samples were subsequently homoge-
nized and centrifuged at 20,000 g for 15 min at 4 °C. To
obtain nuclear and cytosolic fractions, the top super-
natant layer (i.e. non-membrane fraction) was collected.
The remaining pelleted samples were re-suspended in
1X volume of ice-cold methanol aqueous solution, and
underwent centrifugation at 20,000 g (4 °C) for 15 min.
Subsequent precipitant was re-suspended in a 1X vol-
ume of ice-cold isopropanol and hexane (with a 2:1 dilu-
tion ratio), and centrifuged for 15 min at 20,000 g (4 °C).
Resultant “membrane protein pellet fraction” was finally
re-suspended in Triethylamonium bicarbonate (TEAB; 25
mM) and sodium deoxycholate (SDC; 0.5%). From the ori-
ginal supernatant (i.e. the initial non-membrane fraction)
of the first centrifugation step above, samples were resus-
pended in ice-cold methanol at 0.5-fold volume, and cen-
trifuged for 15min at 20,000 g. The resultant “nuclear
protein pellet fraction” were re-suspended in TEAB (25
mM) and SDC (0.5%). The supernatants of centrifuged
samples from the last step were subsequently brought up
in ice-cold methanol at 7-fold volume, followed by centri-
fugation for 15min at 20,000 g, the resultant “cytosolic
protein pellet fractions” were re-suspended in TEAB (25
mM) and SDC (0.5%). For the entire study, we used the
membrane and cytosolic fractions.
Tryptic digestion
A 1:100 enzyme-to-substrate ratio was used for our tryptic
digestion. Briefly, sequencing grade porcine trypsin (Pro-
mega, Wisconsin) was added to 100 μg aliquots of de-
pleted brain homogenate (i.e. cytosolic and membrane
protein extracts) after reduction-alkylation procedure, at a
final protein concentration of 1 μg/μl. Samples were sub-
sequently incubated at 37 °C for 16 h. Ten microliters of
digested samples were dried in a vacuum centrifuge for
anhydrous TMT labeling described below.
Tandem mass tag (TMT) labeling
A multiplexed isobaric labeling strategy (comprising of
the 10-plex TMT labeling platform – ThermoScientific,
Waltham, MA) was used to enable simultaneous identifi-
cation and quantification of proteins from multiple bio-
logical samples. This enabled us to randomize all
samples from all different groups for analyses within the
same batch with the addition of an internal reference
used in each batch. Experimenter was blinded to the
identity of samples for each corresponding isobaric label
tags. Briefly, twenty microliters of each TMT label was
re-suspended in 25 mM TEAB in acetonitrile solution,
and added to 20 μl of dried (digested) protein samples
from each cases. Samples were incubated for 1 h under
room temperature, with the reaction quenched with for-
mic acid to a final concentration of 1% v/v. Labeled sam-
ples from each batch were pooled together based on
their respective experimental batches and subsequently
taken to dryness to remove acetonitrile prior to the SDC
and TEAB cleanup step.
Sample clean up
To remove residual SDC and TEAB from pooled
samples, the dried TMT-labeled (protein) samples were
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Table 1 (A) Top panel shows list of individual cases, their demographics, pathological score at autopsy and randomization of
samples for Tandem Mass Tag isobaric 10-plex multiplexing. (B) Bottom panel shows mean estimates of relevant demographics,
post-mortem interval (PMI) time, pathological score at autopsy for patients across the three different populations investigated
A
Cases Disease CDR score Sex (M/F) Mean plaque
score
Braak-staging (I-VI) TMT isobaric
label
Plex group
1 Healthy Controls 0 F 0 0 -128C Plex A
2 Healthy Controls 0 F 0 I -128N Plex A
3 Healthy Controls 0 M 0 I -129C Plex A
4 Healthy Controls 0.5 M 0 II -128C Plex B
5 Healthy Controls 0 M 0.26 II -128N Plex B
6 Healthy Controls 0 M 0 0 -131 [ref] Plex A, B, C
7 Healthy Controls 0.5 F 0 II -129C Plex B
8 Healthy Controls 0.5 M 0 I -126 Plex C
9 Healthy Controls 0 F 0 0 -127C Plex C
10 Nonagenerians 0 F 5.356 V -127N Plex B
11 Nonagenerians 0 F 1.944 IV -126 Plex A
12 Nonagenerians 0.5 F 3.754 IV -127C Plex A
13 Nonagenerians 0 M 1.95 IV -127N Plex A
14 Nonagenerians 0.5 F 7.49 V -126 Plex B
15 Nonagenerians 0.5 F 7.49 VI -127C Plex A
16 Alzheimer's
Disease
4 M 29.76 VI -129N Plex A
17 Alzheimer's
Disease
3 M 18.88 VI -130C Plex A
18 Alzheimer's
Disease
2 F 19.12 VI -130N Plex A
19 Alzheimer's
Disease
2 F 20.24 VI -129C Plex C
20 Alzheimer's
Disease
1 M 6.72 VI -128C Plex C
21 Alzheimer's
Disease
2 M 12.58 VI -130C Plex C
22 Alzheimer's
Disease
3 F 9.17 VI -127N Plex C
23 Alzheimer's
Disease
1 F 24.15 VI -129N Plex B
24 Alzheimer's
Disease
3 F 20.48 VI -130C Plex B
25 Alzheimer's
Disease
2 M 22.47 VI -130N Plex B
26 Alzheimer's
Disease
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re-suspended in 100 μl of 1% formic acid in LC/MS
grade water, and subsequently centrifuged for 1 min at
20,000 g to remove SDC precipitant. Supernatants were
collected into new tubes, and 400 μl of ethyl acetate was
added, samples were then vortexed and centrifuged for
30 s at 20,000 g to partition residual SDC into the or-
ganic (upper) layer, with the latter discarded. This cycle
was repeated on three occasions to ensure efficient re-
moval of residual SDC, and the final lower phase was
taken to dryness in a speed vacuum. Dried SDC cleaned
samples were subsequently re-suspended in 100 μl of 0.1%
formic acid. Pooled TMT-labeled samples were concen-
trated and de-salted using C18 reversed phase ZipTips fol-
lowing manufacturer’s protocol (Merk Millipore Ltd., Co.
Cork, IRL). Final eluates of ZipTipping were re-suspended
in 20 μl of 0.1% formic acid and transferred into an auto-
sampler vial, for analyses using a nano-Ultra-Performance
Liquid Chromatography (UPLC) MS on a Q-Exactive
Orbitrap instrument (Thermo).
Chromatography and mass spectrometry methods (LC-
MS/MS)
We analyzed our protein samples by LC-MS/MS (Q-
Exactive). Briefly, data dependent acquisition (DDA) set-
tings for the MS experiments followed our previous
work [27, 28]. DDA settings were as follows: full-scan
MS resolution = 140,000 full width at half maximum at
200 m/z, full-scan range = 380–1250m/z, isolation
width = 1.2 m/z, higher energy C-trap dissociation rela-
tive collision energy = 29, a minimum m/z setting of 100
m/z was used for all MS2 spectra, MS2 resolution = 17,
500, dynamic exclusion = 180 s, and a Top 15 high/low
duty cycle was used for precursor ion selection. The
narrow isolation window and the ultra-long gradient
settings “were used to minimize the deleterious effects
on quantitative accuracy that result from co-isolation of
isobaric precursors without resorting to MS3-based
methods” [27, 28].
Data processing and statistical analysis of proteomics
data
We used the PMi preview software to survey our amal-
gamated data-files and, to add other modifications to
our search criteria, if deemed necessary. Preview results
were used to choose the precursor and fragment ion
mass tolerances (4-ppm, 0.02-Da, respectively) and dy-
namic modifications. We used the following settings to
search the data using SEQUEST and BYONIC as the
search algorithms, and Uniprot human database (FEB/
2016). Dynamic modifications - Oxidation / + 15.995 Da
(M), Methyl / + 14.016 Da (E), Deamidated / + 0.984 Da
(N, Q), static modifications of TMT10plex / + 229.163
Da (N-Terminus, K), Carbamidomethyl + 57.021 (C).
We only considered unique peptides for our final
quantification. For SEQUEST, we used the Percolator
feature of Proteome Discoverer, and for Byonic, we used
the target-decoy feature, to set a false discovery rate
(FDR) of 0.01. The peptides passing this stringent cutoff
FDR rate were subsequently exported for data cleaning
and statistical analysis. Proteins only underwent quanti-
tative analysis if they were identified in at least half of
the total number of plexes. A Shapiro-Wilk test for nor-
mality was assessed prior to statistical analyses. Raw ion
counts were ln transformed and analyzed by One-way
analyses of variance (ANOVA) (for 3 group comparison),
t-test (2 group comparison) or spearman correlations to
interrogate for significant proteins between the different
groups. Significantly regulated proteins were subse-
quently uploaded into ingenuity pathway analyses (IPA)
where molecules and pathways unique to each group
comparison(s) were identified. The ratios were formed
by first dividing all samples with the same reference
samples from the control group (see Table 1A) used in
the same plex, and subsequently log2 ratio values were
generated by dividing log2 values between two groups of
interest (i.e. control/AD or control/nonagenarians or
AD/nonagenarians). We have deposited the mass spec-
trometry proteomics into the ProteomeXchange Consor-
tium via the PRIDE partner repository [29]. Our datasets
can be located with the unique identifier - PXD012059.
IPA analysis
We uploaded all datasets of significantly modulated pro-
teins from our group comparisons into the Ingenuity
Pathway Analysis software (IPA, Ingenuity® Systems
[30]) to map those significantly regulated proteins onto
known networks of protein interactions in the knowl-
edgebase. We also used the IPA knowledgebase to fur-
ther ascertain the significantly regulated molecular
pathways “Canonical pathways” and biological signifi-
cance of AD, tau or amyloid dependent changes in pro-
tein expression from each experimental paradigm. For
our core analysis settings, we used the following - In-
genuity Knowledge base as reference set, maximum
number of 35 molecules per network, and maximum
number of 25 networks for analysis. We only considered
experimentally observed knowledge. We also controlled
for species, data sources, tissue type/cell lines at the time
of analysis in IPA. Our core analysis identified canonical
pathways shown to be significantly modulated in re-
sponse to AD, tau or amyloid pathogenesis as a result of
significant modulation of proteins represented in those
pathways. The statistical significance of the association
between the uploaded dataset and the identified canon-
ical pathways were measured using two methods: 1) Ra-
tio of the number of molecules from the data set that
map to a canonical pathway divided by the total number
of molecules in that canonical pathway knowledgebase
Pearson et al. BMC Neurology          (2020) 20:317 Page 5 of 20
in IPA is displayed. 2) Fisher’s exact test, to calculate a
p-value determining the probability that the association
between the proteins in the dataset and the canonical
pathway is explained by chance alone. P-values lower
than 0.01 were only considered significant in these stud-
ies. Upstream regulator analysis in IPA was used to pre-
dict the upstream master regulators in our proteomic
dataset using the Ingenuity® Knowledge Base. An overlap
P values was determined based on analyses of the signifi-
cant overlap between proteins (and their related genes)
in our dataset and known targets regulated by the
Upstream master regulator.
Western blotting analyses
Immunoblotting analyses was conducted on tissue ho-
mogenates prepared for proteomic analyses above. Briefly,
homogenized samples resuspended in TEAB (25mM) and
SDC (0.5%) were first denatured at 95 °C by boiling in
Laemmli buffer (Bio-Rad; Hercules, CA) with reducing
agent. Samples were then resolved on stain free 4 to 20%
gradient polyacrylamide criterion gels (Bio-Rad; Hercules,
CA). After electrotransferring, polyvinylidene difluoride
(PVDF) membranes were blocked in 5% milk (made in
Tris-buffered saline - TBS) and subsequently immuno-
probed with primary antibodies overnight (Neurofilament
medium chain polypeptide [NEFM] and Neurofilament
medium chain polypeptide [NF-H] - ThermoScientific,
Waltham MA; Superoxide dismutase [SOD1] – Abcam,
Cambridge MA). Washed membranes were then probed
with respective horseradish peroxidase (HRP)-linked anti-
mouse and anti-rabbit secondary antibodies (Santa Cruz;
Dallas, TX). Immunoblots were analyzed by using the total
protein quantitation of stain free gels to obtain signal in-
tensity densitometry ratios quantified by chemilumines-
cence imaging using the ChemiDocTM XRS (Bio-Rad;
Hercules, CA).
Results
Demographics and clinical background of patient
population
In this study, we used 26 total brain specimens from the
superior part of the inferior horn of the lateral ventricles
obtained from controls (9 cases), aged-matched controls
(6 cases) and nonagenarians(11 cases) – Table 1A-B. On
average both the nonagenarian (448 ± 110.07) and AD
(441 ± 76.2) groups had a similar post-mortem interval
time; with the control group were 25–27% higher com-
pared to the nonagenarian and AD groups. Control
group were 77.2 ± 0.6 yrs. and AD group 77.2 ± 0.5 yrs.;
while the nonagenarian group were 93.2 ± 1.1 yrs.
Each group had a mixed gender, with 44.4, 83.3 and
54.5% females observed in control-AD, nonagenarian and
AD groups respectively. Controls (0.17 ± 0.08) and nona-
genarian (0.25 ± 0.11) groups showed relatively similar
CDR score; whilst AD group showed significantly higher
CDR scores at (2.36 ± 0.28) as expected. Mean amyloid
plaque score in control, nonagenarian and AD groups were
0.03 ± 0.03, 4.66 ± 1.03 and 19.59 ± 2.36 respectively. Braak
staging score in control, nonagenarian and AD groups
were 1.0 ± 0.3, 4.67 ± 0.03 and 6.0 ± 0.0 respectively.
Proteomic profiles and the cell type distribution of the
superior part of the inferior horn of the lateral ventricles
from autopsy tissue of control, AD and nonagenarian
patients
A 10multiplex TMT isobaric tag approach was used to
study the proteomic profiles in the superior part of the in-
ferior horn of the lateral ventricles of control, AD and
nonagenarian patients. In this study, a total of 18,028 total
peptide spectrum matches, 801 non-redundant master
protein groups, 504 of these master protein groups were
identified within 50% of each plex and groups (Fig. 1a-
table). A one-way ANOVA approach was used to analyze
the master proteins to identify changes in unique and
common proteins significantly changing between control
vs AD vs nonagenarian patients.
Statistical analyses using one-way ANOVA after Benja-
min Hochberg correction identified 22 proteins changing in
the control vs nonagenarian patients, 25 proteins changing
in the control vs AD patients, and 23 proteins changing in
nonagenarian vs AD patient’s (Fig. 1b – see Venn diagram).
In the control vs nonagenarian and control vs AD groups, 3
common proteins were identified to be significantly altered.
In the nonagenarian vs AD and control vs AD groups, 4
common proteins were identified to be significantly altered.
In the control vs nonagenarian and nonagenarian vs AD
groups, 6 common proteins were identified to be signifi-
cantly altered. See Table 2 and Fig. 2 (graph represen-
tation) for the list of significantly altered proteins
between the three different groups.
We interrogated the cell types observed in our proteomic
analyses by identifying proteins (or their related gene IDs)
associated with brain specific cell types in the PanglaoDB
database. A list of gene IDs identified in our proteomic
runs and matched to their potential cell types is shown in
Fig. 1c. We identified 8 markers associated with neurons, 8
markers associated with astrocytes, 4 markers linked to
dendritic cells, 9 markers associated with ependymal/epi-
thelial cells, 13 markers linked to oligodendrocytes, 4
markers associated with brain vascular endothelial cells,
and 4 markers linked to fibroblasts/immune cells. A few of
these markers overlapped with a maximum of two cell
types. Although not an indication of cell density, this gives
an indication of the variety of cell types in our tissue sam-
ples. We additionally interrogated the number of signifi-
cant proteins changing between the different groups that
was associated with the variety of these cell types, and
expressed this as a percentage in Fig. 1d-e. We observed
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that most of the significant changes in proteins observed
between controls vs nonagenarian were associated with
ependymal cells (33%); neurons, endothelia, astrocytes and
oligodendrocytes each had a 16–17% involvement (Fig. 1d).
In nonagenarians vs AD cases most of the significant
changes in proteins were associated with ependymal cells
(33%) and neurons (33%), while astrocytes and endothelial
cells each had a 17% involvement (Fig. 1e). Due to the min-
imal changes in identifiable proteins specifically associated
with these cells types in our significant list of proteins from
control vs AD we could not obtain similar analyses to infer
cell specific changes for this particular comparison.
Disease, biofunctions, canonical pathways and upstream
regulators modulated in the superior part of the inferior
horn of the lateral ventricles in autopsy tissue from
control, AD and nonagenarian patients
A list of 35 diseases and biofunctions modulated in the su-
perior part of the inferior horn of the lateral ventricles of
control vs AD vs nonagenarian patients is shown in Sup-
plementary Table T1. Some of these diseases and biofunc-
tions include alteration in formation of microtubules and
cytoskeleton, vascularization, cell death/apoptosis, prolif-
eration of neuroglia, synthesis of nitric oxide, cell death of
connective tissue cell, microtubule dynamics, migration
and invasion of cells. Ingenuity pathway analyses (IPA)
identified 9 pathways significantly impacted between con-
trol vs nonagenarian group, 12 pathways significantly im-
pacted between control vs AD group and 5 pathways
significantly impacted between nonagenarian vs AD group
(Table 3). In the control vs nonagenarian group, the top 3
pathways significantly regulated were phagosome matur-
ation, tight-junction signaling and D-mannose degrad-
ation. In the control vs AD group, the top 3 pathways
significantly regulated were Amyolateral sclerosis signal-
ing, TCA cycle II, and remodeling of epithelial adherens
junctions. In the nonagenarian vs AD group, the top 3
pathways significantly regulated were Amyolateral scler-
osis signaling, gluconeogenesis I, and glycolysis.
We interrogated Top 5 Upstream Regulators of the
significant proteins identified in our analyses across all
three group comparisons (Fig. 3). IPA analyses identified
a significant overlap in our dataset and known targets
regulated by these five Upstream regulators, namely (in
order of the level of significance) - PPARGC1A (PPARG
Coactivator 1 Alpha a transcriptional co-activator), 14–
3-3 protein gamma (or Protein kinase C inhibitor pro-
tein 1 an adapter protein involved in a variety of signal
Fig. 1 Summary of liquid chromatography/mass spectrometry (LC/MS) and proteomic analyses of tissue from the inferior horn of the lateral
ventricles in Alzheimer’s disease (AD) patients, their aged-matched controls and nonagenarian controls. a Table shows identified total number of
quantified spectra, peptide spectrum matches, non-redundant master protein groups, number of master protein groups identified in 50% of all
plexes and used for analyses. b Venn diagram shows significantly regulated proteins in the comparisons between AD patients, their aged-
matched controls and nonagenarian controls. Green (α) represents nonagenarians vs AD; Yellow (β) represents controls vs nonagenarians; Blue (δ)
represents AD-controls vs AD. c Table shows gene IDs (obtained via the PanglaoDB database) associated with specific cell types identified from
our proteomics study of the lateral ventricle. d and e Pie Charts show cell types with significant changes in proteins/genes associated with those
cells (see C), expressed as a percentage between controls vs nonagenarian (d) and nonagenarians vs AD (e) (due to the minimal changes in
identifiable genes/proteins associated with these cells types between control vs AD we have not included that pie chart herein)
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transduction pathways), PSEN1 (Presenilin 1, a proteo-
lytic subunit of γ-secretase involved in cleavage of many
transmembrane proteins such as APP), MAPT (micro-
tubule associated protein tau gene involved in the pro-
duction of tau cytoskeletal proteins), and APP (amyloid
precursor protein, a transmembrane enzyme cleaved into
soluble APP and amyloid beta peptide). All 5 upstream
regulators were observed from our comparisons between
Control vs AD, control vs nonagenarian and nonagenar-
ian vs AD cases.
Proteomic profiles of the superior part of the inferior
horn of the lateral ventricles in autopsy tissue stratified
to amyloid plaque score and Braak staging
In the low amyloid plaque score (< 10) vs high amyloid
plaque score (> 10) we identified 24 significant proteins
(Fig. 4 – Venn diagram). In the early Braak staging score
(0-II) vs late Braak staging score (IV-VI) we identified 21
significant proteins (Fig. 3 – Venn diagram). There were
5 common proteins significantly changing in both strati-
fying groups (see red highlight in Table 4 and 5). For a
list of significantly altered proteins stratified to amyloid
plaque score and Braak staging groups please see Table 4
and 5.
Disease, biofunctions and canonical pathways modulated
in the superior part of the inferior horn of the lateral
ventricles in autopsy tissue stratified to amyloid plaque
score and Braak staging
A list of 21 diseases and biofunctions modulated in the su-
perior part of the inferior horn of the lateral ventricles of
patients stratified to low amyloid plaque score (< 10), high
Table 2 List of significantly modulated proteins in the inferior horn of the lateral ventricles of AD patients, their aged-matched
controls and nonagenarians. P value represents FDR adjusted p value after ANOVA and Benjamini Hochberg correction. Red –
downregulated across group; Blue – upregulated across group. M.P.A – Master Protein Accession Number
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amyloid plaque score (> 10), early Braak staging (0-II)
and late Braak staging (IV-VI) is shown in Supplemen-
tary Table T2. Some of these diseases and biofunctions
include cell death, necrosis, microtubule dynamics, cell
viability, formation of cytoskeleton and microtubule,
accumulation of filaments, apoptosis of muscle cells,
quantity of cell protrusions, and transport of molecules.
Ingenuity pathway analyses (IPA) identified 11 path-
ways significantly impacted between early Braak staging
(0-II) vs late Braak staging (IV-VI), 14 pathways signifi-
cantly impacted between low amyloid plaque score
(< 10) vs high amyloid plaque score (> 10) (Table 6). In
the group comparisons stratified to Braak staging, the
top 3 pathways significantly regulated were TCA cycle II,
mitochondrial dysfunction and β-alanine degradation I. In
the group comparisons stratified to amyloid plaque
staging, the top 3 pathways significantly regulated
were Amyolateral sclerosis signaling, TCA cycle II,
and RhoA signaling.
Validation of proteins identified from proteomic studies
Three proteins (Neurofilament medium chain polypep-
tide [NEFM], Neurofilament medium chain polypeptide
[NF-H], Superoxide dismutase [SOD1]) were selected
from the list of most significantly regulated proteins
across different groups from our proteomic analyses for
validation of our LC/MS-MS data using antibody based
methods. NEFM and NF-H and SOD1 showed a similar
trend in the direction of changes in control, nonagenar-
ian and AD groups using western blotting technique
compared to findings observed from our proteomic LC/
MS-MS analyses in the same tissue samples (see Supple-
mentary Figure S1:AA’-EE’).
Discussion
Very few studies have explored the pathological changes
to ependymal cells and specialized choroid plexus epi-
thelial cells that line the ventricles in the pathogenesis of
AD. To address this, we employed our state-of-the-art
unbiased proteomic platform to conduct a detailed un-
biased characterization of changes in protein expression
levels, and molecular pathways significantly altered from
autopsy tissue obtained from the walls of the ventricles
(i.e. the superior part of the inferior horns of the lateral
ventricles) in AD cases, their age-matched controls, and
a rare population of non-demented nonagenarians. Mul-
ticiliated ependymal cells predominantly comprise the
epithelial layer lining the walls of the lateral ventricles,
supported by a periventricular niche of different cell
types. Our analyses revealed unique changes in proteins
and molecular pathways that could contribute to AD
pathogenesis and successful ageing.
Ventriculomics changes in AD patients
The lateral ventricles are the two largest cavities of the
ventricular CSF system within the human brain. The in-
ferior horn is the largest horn of the lateral ventricles, it
sits around the temporal lobe and its superomedial por-
tion is one of the localized sites of the choroid plexus.
One of the main roles of this specialized ventricular
structure, is to monitor and maintain both biochemical
and cellular homeostasis of the CNS environment. This
region is also a primary route for exchange between the
blood and the CSF, formed by tight junctions of special-
ized ependyma cells at the blood-CSF barrier (BCSFB).
These barrier functions are maintained by the expression
of numerous membrane transport systems such as ATP-
binding cassette transporters, solute carrier families and
peptide transporters allowing the directed transport of
water, ions, nutrients, and biologically active compounds
into the CSF from the blood [31]. The fenestrated capillar-
ies of the BCSFB also serves as an important site and route
of clearance (eventually into the blood) for brain derived
molecules originating from ISF bulk flow that mix with
the CSF after passing through ependymal cells lining the
walls of the ventricles and glia limitans. Ependyma cells
lining the walls of the ventricles also contribute to the pro-
duction of up to 600ml of CSF per day at a rate of 0.3–
0.6 ml per minute [32]. They are involved in the circula-
tion of 160mls of (adult) CSF through pulsations mediated
by the motion of their ciliated and bulbous microvilli in
combination with the arterial hemodynamics in the plexus
[32]. Trafficking of immune sentinel cells (such as macro-
phages or dendritic cells) also occur across the ependymal
cells lining the walls of the ventricles [33]. Ependymal cells
also have a high protein secretory capacity, that releases
transport proteins, collagen subunits and other cell matrix
proteins, proteases, cytokines, neuropeptides/hormones
and critical neurotrophic factors involved in neuroendo-
crine function, immune homeostasis and neuronal sup-
port/proliferation [34–36].
In pathological ageing (e.g. AD), the brain has been re-
ported to demonstrate evidence of ependymal/epithelial
atrophy, thickening of the basement membrane, stroma fi-
brosis, alterations in BCSFB integrity, deficiencies in CSF
production and composition, enlarged ventricular volume,
increased arachnoid villi resistance, and reduced rate of
lymphatic absorption [18–23]. Moreover, toxic proteins in
pathological ageing (such as amyloid-ß and hyperpho-
sphorylated aggregated tau) feature around periventricular
regions next to the cerebrospinal fluids of the brain (in
and around subependymal cells lining the walls of the ven-
tricles and subpial glial cells), indicating abnormalities in
the movement and clearance of solutes around these ven-
tricular sites [6–14]. The molecular sequelae of events
driving these age-related pathological changes remains
elusive. Studying the molecular response and proteomic
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profiles of these unique cell types and stromal responses
along the walls of the ventricles may thus provide insights
into the age-related neurodegenerative disease state.
Herein, we interrogated autopsy tissue from the walls
of the lateral ventricles of AD and age-matched control
patients using an unbiased proteomic analyses, and re-
vealed a significant increase in 25 proteins. IPA analyses
identified molecular pathways significantly altered be-
tween these two groups, consisting of changes in aspects
of amyotrophic lateral sclerosis signaling, superoxide
radical degradation, tricarboxylic acid cycle (TCA) cycle
and disruptions in several energy metabolic pathways,
remodeling of the epithelial adherens junctions, Fc γ re-
ceptor mediated phagocytosis in macrophages and
monocytes, and RhoA signaling which is implicated in
cytoskeletal dynamics, transcription, cell cycle mainten-
ance and cell development. Some of these effects corre-
lated with the staging of pathology, being more
prominent in Braak stage IV-VI vs Braak Stage I-III. Our
observed changes ostensibly indicate molecular
Fig. 2 Graph showing significantly modulated proteins (their abundance ratio) in the inferior horn of the lateral ventricles AD patients, their
aged-matched controls and nonagenarians. Asterisks denote: *P < 0.05; **P < 0.01; ***P < 0.001. P value represents FDR adjusted p value after
ANOVA (/Tukeys HSD posthoc test) and Benjamin Hochberg correction. δ - control vs AD; β - control vs Nonagenarians; α - Nonagenarians vs AD
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abnormalities in the walls of the lateral ventricles typi-
fied by alterations in mitochondrial bioenergetics, oxida-
tive stress, impaired barrier (BCSFB) integrity,
recruitment of macrophages, and alterations in the cyto-
skeletal organization of cells. To confirm our LC-MS/
MS data we validated a few proteins from our proteomic
profiles using antibody based methods, which showed
similar trends and corroborated our data.
To date, very few studies have utilized an omic platform
to explore the molecular changes to tissue from the walls
of the ventricles during AD pathogenesis. Most studies ap-
pear to have focused primarily on the choroid plexus
using gene arrays. For example, a transcriptomic study
used an Agilent platform with common reference design,
to perform a large scale gene expression analysis and func-
tional annotation of autopsied Choroid Plexus tissue from
patients with Braak stages 0-I and V-VI, including their
age matched controls [37]. Isolated RNA was collected
from laser microdissected Choroid Plexus Epithelium cells
on cryo-sections. Data revealed specific cellular changes
attributed to increased oxidative stress, such as the un-
folded protein response, Eukaryotic Initiation Factor 2
(E1F2) and Nuclear factor erythroid 2-related factor 2
(NRF2) signaling and the protein ubiquitin pathway. They
also noted that BCSFB barrier and paracellular transport
may become more permeable in AD, due to the downreg-
ulation of tight junction protein, Claudin-5. The findings
also predicted loss of choroid plexus epithelium mediated
macrophage recruitment, and down-regulation of (anti-
oxidant) glutathione mediated detoxification pathway and
the urea cycle in AD tissue, suggesting that the choroid
plexus epithelium sink action may be impaired in AD.
In another study, utilizing transcriptome-wide Affyme-
trix microarrays of the extracted lateral ventricular choroid
plexus tissue of AD Braak stage III–VI vs control cases, sig-
nificant upregulation in genes related to metabolic and
immune-related pathways including acute phase response,
cytokine, cell adhesion, interferons, Janus Kinase and Sig-
nal transducer and activator of transcription protein (JAK-
STAT) and Mammalian target of rapamycin (mTOR) were
observed. Downregulated genes included tight-junction
adherens (claudin-5), and genes related to amino acid (me-
thionine) degradation and protein translation [38].
Another recent study utilizing the Brown-Merck Gene
Expression Omnibus database (CP transcripts) to interro-
gate genes in AD vs control choroid plexus tissue also re-
vealed changes in ion transporters (e.g. solute carrier
SLC4A5) and related enzymes (e.g. carbonic anhydrase
CA4), decreased expression of tight junction protein,
claudin-5 involved and mitochondrial ATP synthesis (e.g.
Table 3 Canonical pathways modulated in the inferior horn of the lateral ventricles of AD patients, their aged-matched controls and
nonagenarians. Identified canonical pathways generated from the list of significantly modulated proteins across three groups of
interests using Ingenuity pathway analyses (IPA). FDR adjusted P value after Fischer’s test and Benjamin Hochberg correction
following uploading of significantly regulated proteins into IPA (significant cut-off set at 0.01). Control vs nonagenarians (9 pathways
identified), control vs AD (12 pathways identified), control vs nonagenarians (5 pathways identified). Blue represents upregulated
pathways and Red represents downregulated pathways
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Fig. 3 Top 5 Upstream Regulators in the inferior horn of the lateral ventricles. PPARGC1A (PPARG Coactivator 1 Alpha), 14–3-3 protein gamma (or
Protein kinase C inhibitor protein 1), PSEN1 (Presenilin 1), MAPT (Microtubule associated protein tau gene), and APP (amyloid precursor protein)
were the top five upstream regulators identified by IPA. P values were determined based on analyses of the significant overlap between genes/
proteins in our dataset and known targets regulated by the Upstream master regulator. All 5 upstream regulators were observed from our 3
combinations of Control vs AD, control vs nonagenarian and nonagenarian vs AD cases
Fig. 4 Venn diagram showing list of significant proteins in the inferior horn of the lateral ventricles based on stratification with amyloid plaque
score (low < 10 vs high > 10) and Braak staging (0-II vs IV-VI)
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adenosine triphosphate ATP5L), increased expression of
pro-inflammatory mediator, interleukin 1 receptor like 1
(IL1RL1) and amyloid precursor protein (APBA3), [39].
Further supporting evidence of disruptions to CSF produc-
tion, solute transport at the blood–CSF interface, brain in-
flammatory status, and mitochondrial bioenergetics in AD.
Additionally, in a preceding proteomic study, using the
less stringent 2D difference gel electrophoresis method to
interrogate choroid plexus tissue of patients at different
stages of AD, authors reported dysfunction in cytoskeletal
integrity as one of the main pathogenic events in AD, cor-
roborating our own LC-MS/MS findings [40]. They par-
ticularly noted a significant reduction in moesin at early
stages of AD pathology. Moesin is a member of the ezrin/
radin/ moesin family of actin binding proteins, which plays
a crucial role in the maintenance of cell-to-cell adhesion,
cell shape and motility, and membrane trafficking in chor-
oidal epithelial cells and ciliated ependymal cells lining the
walls of the ventricles. Their activity is regulated by a
RhoA dependent signaling, which was also significantly al-
tered in our proteomic study. Maintenance of cytoskeletal
integrity is crucial to the function of the choroid plexus as
it is need for the assembly and positioning of specialized
intracellular junctions between epithelial cells, needed to
maintain epithelia adherens junction formation and bar-
rier characteristics of the BCSFB. This may further serve
to explain why we and others [37–39] observed alterations
in adherens junction proteins and BCSFB integrity. Dy-
namic changes in the cytoskeleton also serves an import-
ant factor in the cell cycle maintenance and progression of
the choroid plexus epithelial cells and ependymal cells lin-
ing the walls of the inferior horn of the ventricles, needed
to maintain adequate cell numbers required for efficient
production and circulation of CSF. In AD, there is a noted
reduction in CSF production rate [41], reduced water in-
flux (ratio) into the CSF [42–44], and also an elevated CSF
pressure [45]. These CSF changes can have significant ef-
fect on secretion, circulation, absorption and drainage/
clearance processes in the brain of AD patients. Indeed,
studies have shown that clearance rates of Aß are slower
in individuals with AD compared to age-matched controls
[46], while tau production rate in the CSF has also been
shown to positively correlate with amyloidosis in AD [47] .
Our further search of the literature also identified a con-
sistent theme from other studies utilizing (biased) prote-
omic and antibody-based analytical methods, which
corroborated with our studies and other unbiased omic
analyses mentioned above [37–39]. This involved a prom-
inent interplay between defects in energy metabolism and
oxidative stress. For example mitochondrial enzyme de-
fects typified by reductions in cytochrome c oxidase activ-
ity and an increase in the density of cytochrome c
oxidase-deficient choroidal epithelial cells was observed in
the ventricular tissue/choroid plexus epithelium of AD pa-
tients compared to normal aged matched patients [48].
Impairment in the activity and assembly of mitochondrial
respiratory chain complexes I and IV, and upregulation of
mitochondrial stress related (chaperone) proteins (e.g.
heat shock protein (Hsp)60 and (Hsp)90) were also ob-
served in the choroid plexus/ventricles following exposure
to Aβ [49]. Dysfunction in mitochondrial bioenergetics in
the brain parenchyma is one of the earliest deficits ob-
served in AD brains [50]. The ependymal cells lining the
ventricles have a high metabolic demand owing to their
Table 4 List of significantly modulated proteins in the inferior horn of the lateral ventricles based on stratification with amyloid
plaque score (low < 10 vs high > 10). P value represents FDR adjusted p value after ANOVA and Benjamin Hochberg correction. Blue
box – upregulated across group; Red box – downregulated across group. Red highlighted text shows significant proteins
overlapping after stratifying with amyloid plaque scoring and Braak staging (see Table 5)
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high secretory capacity and transport systems, thus subtle
changes in their mitochondrial bioenergetics can diminish
the efficiency of their essential cellular functions.
Damage to mitochondria can also lead to the increased
production of mitochondrial reactive oxygen/nitrogen
species which can trigger oxidative stress and subse-
quently oxidative and nitrative damage to proteins. We
observed an alteration in the degradation of superoxide
free radical species in our studies. Upregulation of nitric
oxide (NO) production has also been reported within the
choroid plexus of AD patients, associated with Aβ de-
posits [51]. This increase in NO plays a negative feedback
role in Aβ-induced mitochondrial dysfunction [52], as the
interaction between NO and cytochrome c oxidase regu-
lates mitochondrial production of reactive oxygen species.
Moreover, reduction in oxidant-induced Nrf2-regulated
gene products such as anti-oxidant Heme oxygenase-1
(HO1), have likewise been observed in the choroid plexus/
ventricles of AD brains, in agreement with low HO-1 pro-
tein levels in the CSF [53, 54]. Anti-oxidant enzyme, alde-
hyde dehydrogenase (ALDH), has also been shown to
reduce with the extent of Braak staging (V-VII vs I-II),
despite an initial increase in early stages (Braak I-II vs con-
trol) of AD pathogenesis [40].
Studies have also confirmed oxidative damage to key
proteins in the choroid plexus compared to other brain re-
gions at early and/or late stages of AD. This includes, sig-
naling protein - 14-3-3, actin regulatory protein -
tropomyosin, and lipid carrier - apolipoprotein A-II [40,
55]. Oxidative damage to these proteins may alter protein-
protein interactions, protein folding and protein kinase ac-
tivity, potentially impairing cell signaling, mitochondrial
function, cilia motility, lipid transport and metabolism [55].
Another hallmark feature observed in our study is the
alteration in the recruitment of inflammatory cells, and a
pro-inflammatory state of cells lining the ventricular tis-
sue in AD brains. To corroborate these findings, in the
aforementioned transcriptomic study by Kant et al.
(2018) [39], a significant increase in interleukin-1 recep-
tor (IL1R) and IL1RL1 was noted in AD vs control cases.
IL1R/IL1RL1 signaling are involved in promoting acute
and chronic inflammation, and could provide a chemo-
tactic gradient to recruit circulating blood borne mono-
cytes, as this region can serve as an interface between
the brain-CSF and the circulation [56]. Similar changes
were also corroborated by other transcriptomic studies
in human choroid plexus tissue typified by altered chor-
oid plexus mediated microphage recruitment [37] and
augmented immune-related pathways including acute
phase response, cytokine, and interferon signaling [38].
This is also supported by studies in chronic advanced
aged mice, where multiorgan genome-wide analysis re-
ported a type I interferon (IFN-I)-dependent gene ex-
pression profile and signature in the choroid plexus [57].
This altered inflammatory state in the choroid plexus
was shown to partially drive cognitive dysfunction and
deficiency in hippocampal neurogenesis as demonstrated
by the restorative effects of blocking IFN-I signaling
[57]. In our study we observed a significant increase in
Fc γ receptor mediated phagocytosis in macrophages
and monocytes in the ventricular tissue of AD compared
to control subjects. Thus it appears that during AD
pathogenesis, there could be an alteration in the traffick-
ing of blood derived macrophage cells into the ventricu-
lar/choroid plexus tissue, which could compromise and
lead to a pro-inflammatory environment.
Table 5 List of significantly modulated proteins in the inferior horn of the lateral ventricles based on stratification with Braak staging
(0-II vs IV-VI). P value represents FDR adjusted p value after ANOVA and Benjamin Hochberg correction. Blue box – upregulated
across group; Red box – downregulated across group. Red highlighted text shows significant proteins overlapping after stratifying
with Braak staging and amyloid plaque scoring (see Table 4)
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A major point of consideration for our study is the
timeline of major pathogenic events in AD and their re-
lationship to changes observed in the lateral ventricles.
Studies have reported high levels of amyloid beta, and
tau accumulation (observed as argyrophilic filaments,
curly fibers, and tangle pathology), in the choroid plexus
of AD patients compared to age-matched non-demented
subjects [58–63]. Thus suggesting a direct relationship
between these pathogenic proteins and the development
of functional and structural deterioration [58]. It remains
undetermined whether amyloidosis and tauopathy in
AD, can occur as a direct consequence of early choroid
plexus/ventricular system deterioration, or whether tau/
amyloid species derived from other brain regions during
AD pathogenesis are the direct mediators of the damage
to the lateral ventricle/choroid plexus tissue. Indeed the
pathobiology of AD starts many years before the manifest-
ation of clinical symptoms, but as we only have access to a
snap shot of each patient at autopsy, we are not able to de-
lineate progression of longitudinal changes.
Nonetheless, we can speculate based on our findings
and those of others that deficits observed in the lateral
ventricles/choroid plexus tissue in AD, are likely to con-
tribute to a deterioration in some of their essential func-
tions (e.g. maintaining BCSFB, CSF production rate,
normal CSF pressure and circulation, absorption and
drainage) which can impact on brain clearance (of Aβ
and tau). In support of this association, studies have
implicated a defect in the uptake, transport and pro-
cessing of AD-related pathogenic proteins by epen-
dymal cells lining the ventricles in AD. For example,
alterations in the expression of endocytotic clearance
receptor, megalin [58, 64–67], subunit of the ubiqui-
tin proteasome activator complex PA28 [40], and
amyloid binding proteins such as transthyretin [58,
68], gelsolin [51], and apolipoprotein J [69], have been
described in ependymal cells lining the ventricles in
AD. Moreorover, other studies have likewise impli-
cated a defective APP/Aβ processing in ependymal
cells in AD [70, 71]. With our studies also supporting
proteasomal and lysosomal deficits typified by reduc-
tions in Ubiquitin-conjugating proteasome enzyme E2,
and a lysosomal ATPase protein subunit.
Proteomic changes in relationship to amyloid pathology
and Braak (tau) staging
Because Alzheimer’s pathology primarily involves tau
and amyloid pathogenesis, we further stratified our data-
sets in all the 26 autopsy cases to demonstrate molecular
pathways that particularly correlate with (low vs high)
amyloid plaque scoring and (early 0-II vs late IV-VI
stage) Braak (phosphorylated [p-tau]) staging. We ob-
served 21 and 24 proteins significantly correlated with
amyloid plaque score and Braak (p-tau) staging,
Table 6 Canonical pathways modulated in the inferior horn of the lateral ventricles after stratification for Braak staging and amyloid
plaque score. Identified canonical pathways generated from the list of significantly modulated proteins after stratifying for low vs
high amyloid plaque score (low < 10 vs high > 10) and early vs late Braak staging (0-II vs IV-VI) using Ingenuity pathway analyses
(IPA). FDR adjusted P value after Fischer’s test and Benjamin Hochberg correction following uploading of significantly regulated
proteins into IPA (significant cut-off set at 0.01). Early vs late Braak staging (11 pathways identified), low vs high amyloid plaque
score (14 pathways identified). Blue represents upregulated pathways and Red represents downregulated pathways
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respectively. Ingenuity pathway analysis identified oxida-
tive stress, impaired TCA cycle II and related micto-
chondrial energy metabolism, and impaired amino acid
degradation were unique to both tau and amyloid path-
ologies. Remodeling of the epithelial adherens junctions,
Fc γ receptor mediated phagocytosis in macrophages
and monocytes and RhoA signaling were among the top
pathways observed to ‘specifically’ correlate with amyloid
score, and could be involved in driving the pathogenesis
of amyloidosis or alternatively be a consequence of sig-
nificant ß-amyloid pathology. Braak staging on the other
hand was uniquely correlated with impairments in iron
homeostasis signaling pathway, superoxide radical deg-
radation and phagosome maturation, and also implicates
these pathological states in either driving tauopathy or
as part of the secondary response to hyperphosphory-
lated tau species in the brain during AD pathogenesis.
Proteomic changes in nonagenarian patients
Age is the greatest risk factor of AD, thus a novel approach
towards investigating the pathogenesis of AD is to interro-
gate nonagenarians who are resilient to AD pathology and
to compare these cases with younger controls and AD cases
at autopsy to build a prospective sequelae of events in AD
pathobiology. We thus conducted a similar study herein to
identify those resilient presumably “successful aging” prote-
omic profiles in the tissue located around the walls of the
inferior horn of the lateral ventricles. Our proteomics ana-
lyses identified 22 proteins significantly changing in the
control vs nonagenarian group. The Top 3 pathways signifi-
cantly regulated in this group comparison were changes in
phagocytic clearance mechanisms (specifically phagosome
maturation), impaired tight-junction signaling involved in
mediating proliferation, differentiation, migration, growth/
survival pathways, and cytokine signaling, and glucose and
mannose metabolism which are key for cellular bioenerget-
ics. These changes could represent a picture of preceding
AD pathology and the ‘non-pathological’ stages in the resili-
ent nonagenarian brain, which could be on an early cogni-
tive continuum towards AD. It is noteworthy that most of
the nonagenarian cases we investigated exhibited Braak
stages of IV-V, despite the low amyloid and CDR score,
suggesting that they may be part of the primary age-related
tauopathy (PART) spectrum [72–75].
When we interrogated the nonagenarian vs AD group,
we observed significant changes in 23 proteins. The top
pathways significantly regulated in this group comparison
were amyotrophic lateral sclerosis signaling implicating an
upregulation in oxidative stress, changes in gluconeogene-
sis and glycolysis pathways indicating an impairment in
mitochondrial bioenergetics, and phosphodiesterase type
5 (PDE5) inhibition which implicates a deficiency in the
vasodilatory effect of smooth muscle cells of the highly
vascularized stroma that could impact on vascular
permeability, inflammation and vascular leakage. These
pathobiological changes unique to these group compari-
sons could represent a novel approach to developing new
strategies to mitigate AD-like pathogenesis. However, fur-
ther studies will be needed in preclinical models to ex-
plore their role in AD pathobiology.
Limitation in attributing protein changes to a distinct cell
type
It is worthy of note that the tissue we examined in the in-
ferior horn of the lateral ventricles contained a mixed cell
population. We utilized the PanglaoDB database [76] to
search for proteins associated with distinct brain cell
types. Our assessment of the list of proteins identified in
the proteomic experiments indicated numerous proteins
associated with epithelial and ependymal cells. However,
proteins indicative of other cell types were also identified,
such as astrocytes, oligodendrocytes, neurons, endothelia,
fibroblasts, dendritic/immune cells. Thus our studies
should be interpreted accordingly, as the significant
changes in proteins identified may originate from different
cell types and not only the ependymal/epithelial cells.
Intriguingly, we were able to demonstrate that of the 7
different brain cell types, most of the significant changes
in cell-specific proteins observed between controls vs
nonagenarian cases were associated mainly with epen-
dymal cells. While in nonagenarians vs AD cases epen-
dymal cells and neurons ranked highest. Future work
using single cell isolation from fresh tissue would be in-
teresting to specifically identify single cell changes at the
protein (LC-MS/MS or IHC) and/or gene (e.g. 10x gen-
omics or microdissection) levels in a similar cohort.
Conclusion
In this study, we hypothesized that molecular aberra-
tions (at the protein level) in the unique cell types lining
the walls of the lateral ventricles and nearby surrounding
regions, may compromise their physiological properties
and essential functions, which could act as a medium for
contributing towards AD pathogenesis. We identified
top molecular pathways significantly altered in AD
pathogenesis involving impaired mitochondrial bioener-
getics, oxidative stress, remodeling of epithelia adherens
junction barrier, recruitment of macrophage/monocytes
and increase in their phagocytic activity, and alterations
in cytoskeletal dynamics. These appeared to be driven by
upstream regulators PPARGC1A, 14–3-3 protein γ,
PSEN1, MAPT and APP genes. Oxidative stress, im-
paired amino-acid metabolism, and mitochondrial bio-
energetics were observed in the AD tissue irrespective of
tau or amyloid staging. Additionally, remodeling of the
epithelial adherens tight junctions, Fc γ receptor medi-
ated phagocytosis in macrophages and monocytes, and
RhoA signaling and its impact of cytoskeletal dynamics
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were unique and specific to amyloid pathology. While
Tau pathology was uniquely correlated with altered iron
homeostasis signaling pathway, superoxide radical deg-
radation and phagosome maturation.
Although our studies are unable to determine whether
disrupted cellular functions in the lateral ventricles pre-
cede AD pathology, it appears that significant molecular
changes within this brain region may be, at least, one of
the contributing factor in AD pathogenesis. As there are
multifactorial changes observed in AD, which can also
be compounded by genetic (e.g. apolipoprotein E4) and
environmental insults (e.g. brain injury), more studies in
a larger prospective cohort are need to elucidate the role
of this brain region in AD. In particular, developing
in vivo imaging methods to assess brain ventricle/chor-
oid plexus function and CSF biofluid dynamics in living
patients at pre, peri and post onset of pathology. Our
findings are also significant because considering that
some of the proteins identified can be secreted or re-
leased into the extracellular environment, they could
therefore serve as potential biomarkers in the blood/CSF
for AD pathogenesis, particularly those changing at the
earliest and most crucial stages or inflection point of the
disease (i.e. those unique to nonagenarians or AD).
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tions generated from the list of significantly modulated proteins across
three groups of interest using Ingenuity pathway analyses (IPA). Value
represents FDR adjusted p value after Fischer’s test and Benjamin Hoch-
berg correction following uploading of Log2Ratio values of significantly
regulated proteins into IPA. Red box – downregulated across group; Blue
box – upregulated across group.
Additional file 2: Table S2. Disease and Biofunctions modulated in the
inferior horn of the lateral ventricles after stratification for Braak staging
and amyloid plaque score. Underlying disease pathology and
biofunctions generated from the list of significantly modulated proteins
after stratification for Braak staging (0-II vs IV-VI) and amyloid plaque score
using Ingenuity pathway analyses (IPA). Value represents FDR adjusted p
value after Fischer’s test and Benjamin Hochberg correction following
uploading of Log2Ratio values of significantly regulated proteins into IPA.
Red box – downregulated across group; Blue box – upregulated across
group.
Additional file 3: Figure S1. Validation of NEFM, NFH and SOD1 by
western blotting. Validation of proteomic changes using antibody based
methods. Figure shows comparisons of changes in expression of three
proteins (Neurofilament medium chain polypeptide [NEFM] – AA’,
Neurofilament medium chain polypeptide [NF-H] – BB’, Superoxide
dismutase – CC’) in AD, age-matched controls and nonagenarian cases
between antibody based measurement using western blotting and our
proteomic LC-MS/MS analyses. Data(±SEM) represents intensity values
normalized to total protein from stain-free gels. Immunoblotting images
(DD’) and stain free gel images (EE’) are depicted for membrane/gel 1#
and membrane 2# (respectively). Sample size N = 6 control (C); N = 9 non-
agenerian (N) and N = 11 AD (A). The first 3 lanes in gel E/E’ contained
the same reference samples for normalization, these lanes are cropped in
D/D’. Samples with Low total abundant proteins in the gel were not
analyzed.
Abbreviation
ATP5L: Adenosine triphosphate; ALDH: Aldehyde dehydrogenase;
AD: Alzheimer’s disease; APBA3: Amyloid precursor protein; APP: Amyloid
precursor protein; Aß: Amyloid-ß protein; ANOVA: Analysis of variance;
APOE4: Apolipoprotein E4; BCSFB: Blood-CSF barrier; CSF: Cerebrospinal fluid;
CDR: Clinical dementia rating; CERAD: Consortium to Establish a Registry for
Alzheimer’s Disease; DDA: Data dependent acquisition; E1F2: Eukaryotic
Initiation Factor 2; FDR: False discovery rate; GEO: Gene Expression Omnibus;
GFAP: Glial fibrillary acidic protein; Hsp: Heat shock protein; HO1: Heme
oxygenase-1; IHC: Immunohistochemistry; IPA: Ingenuity pathway analyses;
IRB: Institutional Review Board; IFN-I: Interferon type I; IL1RL1: Interleukin 1
receptor like 1; IL1R: Interleukin-1 receptor; ISF: Interstitial fluid; JAK-STAT
: Janus Kinase and Signal transducer and activator of transcription protein;
mTOR: Mammalian target of rapamycin; LC-MS: Liquid chromatography/mass
spectrometry; NFT: Neurofibrillary Tangle; NEFM: Neurofilament medium
chain polypeptide; NF-H: Neurofilament medium chain polypeptide;
NO: Nitric oxide; NRF2: Nuclear factor erythroid 2-related factor 2;
PBS: Phosphate buffer saline; PDE5: Phosphodiesterase type 5; p-
tau: Phosphorylated tau protein; PART: Primary age-related tauopathy;
PA28: proteasome activator complex; S100 β : S100 calcium-binding protein
B; NaCl: Sodium Chloride; SDC: Sodium deoxycholate; SLC4A5: Solute carrier
gene; TMT: Tandem mass tags; TCA: Tricarboxylic acid cycle;
TEAB: Triethylamonium bicarbonate; UPLC: Ultra-Performance Liquid
Chromatography
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